New York, NY -- (SBWIRE) -- 03/30/2017 -- Cardiac Marker Analyzer, also known as Cardiac Reader Systems, provides high point-of-care testing solutions for the diagnosis of myocardial infarction and other cardiac-related diseases. It performs all cardiac monitoring tests, such as myoglobin and cardiac troponin tests, through immunochromatographic assays. A Cardiac Marker Analyzer increases its efficacy and accuracy with special features, such as software, which provides an internal standard to diagnostic procedures and built in LCD displays for the visualization of practices. Cardiac Marker Analyzers are important for the prevention of the misdiagnoses of cardiac conditions.

A sample of this report is available upon request @ http://www.persistencemarketresearch.com/samples/3479

Some of the major Cardiac Marker Analyzers which are frequently used in diagnosis of cardiac conditions include QL Care Analyzer, Meritas POC Analyzer, PATHFAST Analyzer, Alere Meterpro Analyzer, RAMP Reader, RAMP 200, i–STAT System, Stratus CS Analyzer, Cobas H 232 POC System, Access 2 Immunoassay System, DXpress Reader Analyzer and ichroma DUO Analyzer.

In terms of geographic, North America and Europe dominates the global Cardiac Marker Analyzer market. This is due to increasing prevalence of cardiac related diseases in these regions. The U.S. represents the largest market for Cardiac Marker Analyzer followed by Canada in North America. In Europe, France and Germany holds major share of Cardiac Marker Analyzer market. However, Asia is expected to show high growth rates in the next five years in the global Cardiac Marker Analyzer market due to increasing awareness among people about cardiovascular diseases. This increasing awareness increases the demand of Cardiac Marker Analyzer for diagnosis of heart diseases. In addition, less stringent regulatory environments attract manufacturing companies to construct their research facilities in the region which further support in the growth of Cardiac Marker Analyzer in the region. Japan, China and India are expected to be the fastest growing Cardiac Marker Analyzer markets in Asia.

In recent time, increasing prevalence of cardiovascular diseases, such as angina pectoris and myocardial infarction, and technological advancement in marker technology are some of the major drivers for the global Cardiac Marker Analyzer market. In addition, rising number of geriatric populations and technological advancement in cardiac assist devices are also supporting in the growth of global Cardiac Marker Analyzer market. Aged people are more susceptible towards cardiac diseases compared to youngster. Thus, geriatric people increase the demand of Cardiac Marker Analyzer for the management of their cardiac disorders. Moreover innovative applications of Cardiac Marker Analyzer, such as less time consuming practices and provides accurate diagnostic results, have also fueled the growth of the market. It takes less than 14 minutes to complete a diagnostic test. Increasing prevalence of diabetes and obese people develops opportunity for the global Cardiac Marker Analyzer market. However, stringent regulations and cost constrains are some of the major restraints of the global Cardiac Marker Analyzer market. In addition, presence of alternative technologies for the diagnosis of cardiac diseases also obstructs the growth of global Cardiac Marker Analyzer market. Increasing mergers and acquisitions between major players is key trend for the global Cardiac Marker Analyzer market.

To view TOC of this report is available upon request @ http://www.persistencemarketresearch.com/toc/3479

Some of the major companies operating in the global Cardiac Marker Analyzer market are Mitsubishi Chemical Medience Corporation, CardioGenics, Trinity Biotech, Lifesign, Abbott, Siemen Healthcare, Boditech and Beckman Coulter.